- Home
- GLPG vs CMPO Comparison
GLPG vs CMPO Comparison
Compare GLPG & CMPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- CMPO
- Stock Information
- Founded
- GLPG 1999
- CMPO 2000
- Country
- GLPG Belgium
- CMPO United States
- Employees
- GLPG N/A
- CMPO N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- CMPO Finance: Consumer Services
- Sector
- GLPG Health Care
- CMPO Finance
- Exchange
- GLPG Nasdaq
- CMPO Nasdaq
- Market Cap
- GLPG 2.1B
- CMPO 2.1B
- IPO Year
- GLPG 2005
- CMPO N/A
- Fundamental
- Price
- GLPG $34.45
- CMPO $20.18
- Analyst Decision
- GLPG Sell
- CMPO Strong Buy
- Analyst Count
- GLPG 3
- CMPO 6
- Target Price
- GLPG $26.00
- CMPO $17.67
- AVG Volume (30 Days)
- GLPG 203.5K
- CMPO 974.1K
- Earning Date
- GLPG 10-29-2025
- CMPO 11-07-2025
- Dividend Yield
- GLPG N/A
- CMPO N/A
- EPS Growth
- GLPG N/A
- CMPO N/A
- EPS
- GLPG N/A
- CMPO N/A
- Revenue
- GLPG $323,674,692.00
- CMPO $267,817,999.00
- Revenue This Year
- GLPG $1.77
- CMPO $10.30
- Revenue Next Year
- GLPG $0.44
- CMPO $8.12
- P/E Ratio
- GLPG N/A
- CMPO N/A
- Revenue Growth
- GLPG 5.43
- CMPO N/A
- 52 Week Low
- GLPG $22.36
- CMPO $9.24
- 52 Week High
- GLPG $37.78
- CMPO $21.00
- Technical
- Relative Strength Index (RSI)
- GLPG 53.87
- CMPO 57.25
- Support Level
- GLPG $32.37
- CMPO $19.71
- Resistance Level
- GLPG $37.78
- CMPO $20.53
- Average True Range (ATR)
- GLPG 0.77
- CMPO 0.62
- MACD
- GLPG 0.00
- CMPO -0.14
- Stochastic Oscillator
- GLPG 39.37
- CMPO 47.83
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.